Stimulation of autophagy prevents intestinal mucosal inflammation and ameliorates murine colitis.

Abstract

Defective autophagy contributes to the pathogenesis of inflammatory disorders such as inflammatory bowel disease and there are interactions between autophagy and inflammation. Here we have analysed the effects of autophagy stimulators on murine colitis. Mice were treated with intrarectal administration of 2,4,6-trinitrobenzenesulfonic acid (TNBS) (3.5mg·20g-1 ) and body weight was measured daily. Histological damage was scored 2 or 4days after treatment. Some mice received trehalose (3% in drinking water 3weeks before TNBS administration) or a daily administration of rapamycin (1.25mg·kg-1 , i.p.), betanin (1g·kg-1 , i.p.) or betanin+3-methyladenine (3MA) (10mg·kg-1 , i.p.). Protein levels of p-mTOR, p62, LC3, BCL10, NFκB, IκBα and p-IκBα in mucosa were determined by Western blots and mRNA expression of TNFα, IL1β, IL6, IL10, COX2, CCR7, CD11c, inducible NOS and CD86 by qRT-PCR. Impaired autophagy associated with body weight loss and intestinal damage was detected in the mucosa of TNBS-treated mice. Administration of trehalose, rapamycin or betanin prevented the impaired autophagic flux induced by TNBS and decreased mucosal protein levels of BCL10, p-IκBα and NFκB-p65 and the expression of pro-inflammatory cytokines and M1 macrophage markers. Blockade of autophagosome formation by treatment with 3MA, prevented the reduction in protein levels of p62, BCL10, p-IκBα and NFκB-p65 induced by betanin in TNBS-treated mice and weakened the protective effects of betanin on murine colitis. Pharmacological stimulation of mucosal autophagy reduced intestinal inflammation and improved murine colitis.